Collected Studies on Immunity

Ehrlich, Paul R.; Bolduan, Charles F.; Howard,

doi:10.1097/00005053-190708000-00032

Cited by 40 publications

(43 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…C oncomitant tumor immunity, first reported by Ehrlich (1) and Bashford et al (2), is a phenomenon in which an immunogenic tumor-bearing host rejects inoculums of a similar tumor at a distant site, in a wide variety of tumor models (1)(2)(3)(4)(5). Nevertheless, a few investigators have found this response to be transient, as the immunity can decay as the primary tumor progresses.…”

mentioning

confidence: 99%

Effector/Memory but Not Naive Regulatory T Cells Are Responsible for the Loss of Concomitant Tumor Immunity

Lin¹,

Chang

Huang³

et al. 2009

The Journal of Immunology

View full text Add to dashboard Cite

The phenomenon of concomitant tumor immunity involves a tumor-bearing host rejecting another similar tumor at a distant site and suggests the existence of tumor-specific immunity. Loss of this immunity may contribute to tumor metastasis. However, mechanisms underlying the loss of concomitant immunity are largely unknown. We set up a concomitant tumor immunity model in which this immunity is gradually lost as the primary tumor progresses. We found that CD8+ T cells, especially tumor-infiltrating CD8+ T cells, from mice that lost concomitant tumor immunity, possessed potent antitumor properties and strongly expressed effector molecules. Furthermore, effector/memory regulatory T cells (Treg cells, CD103+CD4+Foxp3+ T cells) increased as the primary tumor progressed. They initially accumulated around the tumor and in the spleen at later points. Not only did these cells more greatly express killing molecules, they also suppressed the functions of tumor-bearing CD8+ T cells in vitro and in vivo. Finally, we show that these effector/memory Treg cells inhibit concomitant tumor immunity in vivo. Taken together, data suggest that effector/memory Treg cells are responsible for the loss of concomitant tumor immunity associated with tumor progression.

show abstract

mentioning

confidence: 99%

Effector/Memory but Not Naive Regulatory T Cells Are Responsible for the Loss of Concomitant Tumor Immunity

Lin¹,

Chang

Huang³

et al. 2009

The Journal of Immunology

View full text Add to dashboard Cite

show abstract

“…5x10 5 CHLA-136 cells per well were plated in complete IMDM medium (3 ml) into flat-bottom 6well plates. Cells were exposed to 4-HPR, PPPP alone or in combination as described above.…”

Section: Western Blot Analysismentioning

confidence: 99%

Fenretinide sensitizes multidrug-resistant human neuroblastoma cells to antibody-independent and ch14.18-mediated NK cell cytotoxicity

et al. 2012

View full text Add to dashboard Cite

“…The idea of targeted therapy was first postulated by Paul Ehrlich (1906), with the objective being the attainment of therapeutically effective doses while preserving the state of healthy tissue. [42][43][44][45] As previously highlighted, the path to effective drug delivery to tumor tissue and successful treatment outcomes is marred by a multitude of factors, not least of which is compromised bioaccessibility, and thereby poor bioavailability of antineoplastic drugs at tumor sites.…”

mentioning

confidence: 99%

Overview of the role of nanotechnological innovations in the detection and treatment of solid tumors

Frank¹,

Tyagi²,

Tomar³

et al. 2014

IJN

View full text Add to dashboard Cite

Nanotechnology, although still in its infantile stages, has the potential to revolutionize the diagnosis, treatment, and monitoring of disease progression and success of therapy for numerous diseases and conditions, not least of which is cancer. As it is a leading cause of mortality worldwide, early cancer detection, as well as safe and efficacious therapeutic intervention, will be indispensable in improving the prognosis related to cancers and overall survival rate, as well as health-related quality of life of patients diagnosed with cancer. The development of a relatively new field of nanomedicine, which combines various domains and technologies including nanotechnology, medicine, biology, pharmacology, mathematics, physics, and chemistry, has yielded different approaches to addressing these challenges. Of particular relevance in cancer, nanosystems have shown appreciable success in the realm of diagnosis and treatment. Characteristics attributable to these systems on account of the nanoscale size range allow for individualization of therapy, passive targeting, the attachment of targeting moieties for more specific targeting, minimally invasive procedures, and real-time imaging and monitoring of in vivo processes. Furthermore, incorporation into nanosystems may have the potential to reintroduce into clinical practice drugs that are no longer used because of various shortfalls, as well as aid in the registration of new, potent drugs with suboptimal pharmacokinetic profiles. Research into the development of nanosystems for cancer diagnosis and therapy is thus a rapidly emerging and viable field of study.

show abstract

Collected Studies on Immunity

Cited by 40 publications

References 0 publications

Effector/Memory but Not Naive Regulatory T Cells Are Responsible for the Loss of Concomitant Tumor Immunity

Effector/Memory but Not Naive Regulatory T Cells Are Responsible for the Loss of Concomitant Tumor Immunity

Fenretinide sensitizes multidrug-resistant human neuroblastoma cells to antibody-independent and ch14.18-mediated NK cell cytotoxicity

Overview of the role of nanotechnological innovations in the detection and treatment of solid tumors

Contact Info

Product

Resources

About